Skip to main content Skip to left-side content

Campus Calendar

Aug27
Medical Grand Rounds
8/27/2014 12:15 PM - 1:15 PM
Basic Sciences Education Building, E. Lecture Hall

Title:
Potential Implications of Lowering Gram-negative bacilli MIC Breakpoints for β-lactam Antibiotics

Speakers:
Chris Gentry, PharmD, Clinical Coordinator, and Clinical Specialist, Infectious Diseases Pharmacy Service, Oklahoma City VA Medical Center

Objectives:
Upon completion of this activity, participants will be able to: Identify recent methods utilized to determine a minimum inhibitory concentration (MIC) breakpoint for a β-lactam antibiotic against Gram-negative bacilli.  To describe 2 potential benefits of lowering MIC breakpoints for β-lactam antibiotics against Gram-negative bacilli.  To describe 2 potential hazards of lowering MIC breakpoints for β-lactam antibiotics against Gram-negative bacilli.  To explain the limited clinical outcomes data available to assess the effects of lowering MIC breakpoints for β-lactam antibiotics against Gram-negative bacilli. 

Disclosure Report:  Course Director:  Dr. Michael Bronze has no financial relationships or affiliations to disclose.  Planning Committee Members:  Dr. Ben Cowley has been a consultant for Otsuka.  Dr.  Courtney Houchen has grants/research support in that he is the Co-Founder of COARE Biotechnology.  Dr. James Lane has received grants/research support from Novo Nordisk, VM BioPharma, EMD Serono, Inc, Merck Sharp & Dohme Corp, Eli Lilly and Company, Sanofi-Aventis, Merck/Pfizer, and Genkyotex.  Dr. Dwight Reynolds has received grants/research support from Medtronic.  He has been a consultant for Medtronic.  He has received honorarium from Medtronic.  Dr. Ming Zou has grants/research support from NIH and AHA.  Drs. Rhett Jackson, Adam Asch, Douglas Drevets, Brent Brown, and Mary Beth Humphrey have no financial relationships or affiliations to disclose.  Course Contact:  Ms. Brenda Wilkerson has no financial relationships or affiliations to disclose. Speakers:  Dr. Abu-Fadel has received honorarium form Abbott Vascular.  Speaker:  Dr. Gentry has disclosed grants/research support from Durata Pharmaceuticals, Inc.

Disclaimer Statement:  Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.  Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted.  However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

For further information contact:
Brenda Wilkerson
271-6651 ext. 54374
brenda-wilkerson@ouhsc.edu